Buy or sell CRISPR Therapeutics stock pre IPO via an EquityZen fund
CRISPR Therapeutics Stock
CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform.
About CRISPR Therapeutics Stock
CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.
Founder & CFO
Founder & Chief Executive Officer
Chief Scientific Officer
Forbes - Nov, 19 2019
TechCrunch - Nov, 26 2018
TechCrunch - Nov, 25 2018
Nasdaq Place (press release) - Jun, 26 2018
StreetInsider.com - Jun, 16 2018
Seeking Alpha - Jun, 11 2018
Xconomy - May, 30 2018